The 70% figure refers to the program, not the compound. The work on characterizing and reverse engineering Copaxone was 100% complete when the ANDA was submitted to the FDA in late 2007.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”